GlassScriptPhysician profile
Larry E Krevolin
NPI 1265532923
$40,260.04
in general payments reported to CMS, 2019-2025
34 companies · $5,273 in 2025
The $5,273 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $3,767 · 2021: $8,304 · 2022: $17K · 2023: $4,026 · 2024: $1,139 · 2025: $5,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,930 · Food and Beverage: $3,598 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,676 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,930.00 |
| Food and Beverage | $3,598.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,676.00 |
| Education | $233.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $25,085.67 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $7,278.52 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $1,145.01 | 2019-2024 | Veltassa |
| Amgen INC. | $887.10 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Opko Pharmaceuticals, LLC | $858.76 | 2019-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $854.45 | 2019-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $423.60 | 2019-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $384.93 | 2019-2024 | Velphoro, Korsuva |
| Novo Nordisk INC | $376.67 | 2023-2025 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $316.63 | 2023-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $311.63 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $310.39 | 2020-2024 | Acthar |
| Glaxosmithkline, LLC. | $239.79 | 2020-2023 | Benlysta |
| Ardelyx, INC. | $207.92 | 2024-2025 | Ibsrela |
| Arbor Pharmaceuticals, INC. | $204.23 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $198.01 | 2022-2025 | Tarpeyo |
| Pharmacosmos Therapeutics INC. | $160.18 | 2021 | |
| Horizon Therapeutics Plc | $123.23 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $106.87 | 2021-2023 | Lupkynis |
| Biomerieux INC | $102.93 | 2019 | |
| Akebia Therapeutics INC | $88.12 | 2020-2025 | Vafseo, Auryxia |
| Alexion Pharmaceuticals, INC. | $70.92 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $68.85 | 2019 | |
| Lilly USA, LLC | $68.69 | 2023-2025 | Jardiance |
| Octapharma USA, INC. | $65.44 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $55.73 | 2023-2024 | Edarbyclor, Edarbi |
| Genzyme Corporation | $46.99 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.54 | 2023-2024 | Jardiance |
| Daiichi Sankyo INC. | $43.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.12 | 2023 | Gattex |
| Scpharmaceuticals INC. | $30.41 | 2025 | |
| Amarin Pharma, INC. | $28.46 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $22.80 | 2025 | Empaveli |
| Ultragenyx Pharmaceutical INC. | $15.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Krevolin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.